<h4>Background</h4>Combination molecular targeted therapy with dabrafenib plus trametinib has been shown to improve progression-free survival and overall survival in patients with BRAF V600 mutated unresectable or metastatic melanoma. The gene discussed is BRAF; the disease is metastatic melanoma.